Codiak BioSciences (NASDAQ:CDAK – Get Rating) issued its quarterly earnings data on Thursday. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.47, MarketWatch Earnings reports. Codiak BioSciences had a negative net margin of 162.01% and a negative return on equity of 135.41%.
CDAK stock traded down $0.20 during mid-day trading on Friday, hitting $2.89. The company had a trading volume of 47,188 shares, compared to its average volume of 151,454. Codiak BioSciences has a 12-month low of $2.82 and a 12-month high of $27.09. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.48. The company has a 50-day moving average price of $4.85 and a 200 day moving average price of $8.56.
Several research analysts recently weighed in on CDAK shares. Zacks Investment Research downgraded shares of Codiak BioSciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 26th. The Goldman Sachs Group started coverage on shares of Codiak BioSciences in a report on Friday, February 11th. They issued a “buy” rating and a $19.00 target price for the company. Finally, Wedbush dropped their target price on shares of Codiak BioSciences from $34.00 to $24.00 and set an “outperform” rating for the company in a report on Tuesday, February 22nd.
Codiak BioSciences Company Profile (Get Rating)
Codiak BioSciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors.
- Get a free copy of the StockNews.com research report on Codiak BioSciences (CDAK)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
Receive News & Ratings for Codiak BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codiak BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.